Clinical Trials
Below is a listing of clinical trials conducted at MUSC Hollings Cancer Center. Use the tools in the left toolbar to refine your search. If you are interested in Early Phase/Multi Tumor trials, select the program “Phase I Unit.” Please note that cohort information for the Phase I trials changes often.
| Protocol | Title | Status | Docs |
|---|---|---|---|
| 104390 | Expanded Access Program To Treat Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma with Daraxonrasib | OPEN TO ACCRUAL |
|
| 104365 | PHASE III TRIAL OF RADIOTHERAPY FOLLOWED BY ADJUVANT TEMOZOLOMIDE IN COMBINATION WITH THE IDH INHIBITOR VORASIDENIB VS. PLACEBO IN IDH-MUTATED NEWLY-DIAGNOSED GRADE 3 ASTROCYTOMAS | OPEN TO ACCRUAL |
|
| 104360 | A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients | OPEN TO ACCRUAL |
|
| 104358 | Racial Differences in Patient-Reported Quality of Life Among Prostate Cancer Patients Across Treatment Modalities | OPEN TO ACCRUAL |
|
| 104356 | Case-Control Study of a Novel Test for the Early Detection of Hepatocellular Carcinoma in at-risk Patients with Cirrhosis | OPEN TO ACCRUAL |
|
| 104345 | Accelerating Translation to Practice: Multi-Level Interventions for Efficient Care Coordination Across Medical Specialties | OPEN TO ACCRUAL |
|
| 104339 | The Caris Biorepository Research Protocol | OPEN TO ACCRUAL |
|
| 104336 | Optimizing Clinical Screening for Body Image Distress Among Head and Neck Cancer Survivors: Implementation of a Short Form of the IMAGE-HN Questionnaire | OPEN TO ACCRUAL |
|
| 104333 | A Phase II Randomized Trial of Neoadjuvant Chemotherapy or Chemo-Immunotherapy in Patients with Recurrent/Persistent PD-L1 Enriched Squamous Cell Carcinoma of the Head and Neck Undergoing Salvage Surgery (NEOPOLIS) | OPEN TO ACCRUAL |
|
| 104331 | PRIMary care Engagement in Survivorship (PRIMES): A Mixed Methods Study | OPEN TO ACCRUAL |
|
| 104330 | Blue Light Cystoscopy with Cysview Registry | OPEN TO ACCRUAL |
|
| 104319 | Implementation of a Pilot Program for Opportunistic Salpingectomy at the Time of Gastrointestinal Surgery at MUSC: An Evaluation of Patient and Provider Knowledge and Attitudes | OPEN TO ACCRUAL |
|
| 104314 | A Qualitative Study Exploring the Lived Experiences of Adolescent and Young Adult Head and Neck Cancer Survivors: A Semi-Structured Interview | OPEN TO ACCRUAL |
|
| 104310 | Assessing the Feasibility of Using HPV Testing with Self-collection to Improve Cervical Cancer Screening in MUSC | OPEN TO ACCRUAL |
|
| 104301 | Integrating Narratives for Social Impact for Guiding Health Transformation | OPEN TO ACCRUAL |
|
| 104299 | A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7 + 3) vs (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger Who are Considered High-Risk (Adverse) Acute Myeloid Leukemia As Determined by MYELOMATCH; A MYELOMATCH Clinical Trial | OPEN TO ACCRUAL |
|
| 104296 | Magnetic Cell Selection System for CD34+ Cells from HPC-apheresis used in Treatment of Acute Myeloid Leukemia (AML) | OPEN TO ACCRUAL |
|
| 104292 | CA266-0008: ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC) | OPEN TO ACCRUAL |
|
| 104289 | A randomized Phase III Study to Evaluate Benefits of Autologous Stem Cell Transplant in Patients with Peripheral T-Cell Lymphoma That Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT) | OPEN TO ACCRUAL |
|
| 104287 | Characterizing Dyadic Communication Challenges and Support Needs in Young Adults Caring for a Parent with Metastatic Cancer | OPEN TO ACCRUAL |
|
| 104286 | A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer | OPEN TO ACCRUAL |
|
| 104285 | A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer | OPEN TO ACCRUAL |
|
| 104275 | Examining Emotional Health and Symptom Needs in Long-Term Cancer Survivors Living with Likely Incurable Cancer: Administrative Supplement to IMPACT R01 | OPEN TO ACCRUAL |
|
| 104272 | Expanded Access Program of AMTAGVI that is Out of Specification for Commercial Release | OPEN TO ACCRUAL |
|
| 104271 | A012303: ShortStop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer Who Achieve pCR After Neoadjuvant Chemotherapy with HER2 Blockade | OPEN TO ACCRUAL |
|
| 104270 | Omission of Post-Operative Radiation in Patients with Intermediate Pathological Risk Features and Negative Two Week Post-Operative ctHPVDNA (OPERATION Trial) | OPEN TO ACCRUAL |
|
| 104269 | B-Brilliant | OPEN TO ACCRUAL |
|
| 104267 | NRG-GU015: The Phase III Adaptive Radiation and Chemotherapy for Muscle Invasive Bladder Cancer Trial (ARCHER) | OPEN TO ACCRUAL |
|
| 104266 | S2417CD: A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention Called Current Together after Cancer (CTAC) to Promote Guideline-Concordant Colorectal Cancer Surveillance | OPEN TO ACCRUAL |
|
| 104263 | A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or Without Cemiplimab (REGN2810) for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study) | OPEN TO ACCRUAL |
|
| 104262 | TulmiSTAR-02: A Two-part Phase I Dose Escalation Study of Tulmimetostat (DZR123) in Combination with Darolutamide or Abiraterone Followed by Open-label, Randomized, Phase II Dose Expansion Study to Assess the Safety and Efficacy of Tulmimetostat in Combination with Darolutamide Versus Darolutamide Alone in Patients with Metastatic Hormone Sensitive Prostate Cancer | OPEN TO ACCRUAL |
|
| 104261 | Surgical drain fluid for detection of molecular residual disease (MRD) in patients with bladder, renal, and urothelial cancers | OPEN TO ACCRUAL |
|
| 104257 | Impact of COG KidsCare App on Pediatric Cancer Caregiver Stressors | OPEN TO ACCRUAL |
|
| 104253 | NRG-CC015: Harnessing E-mindfulness Approaches for Living After Breast Cancer - HEAL ABC | OPEN TO ACCRUAL |
|
| 104250 | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy | OPEN TO ACCRUAL |
|
| 104249 | GAIN-BCG: Gemcitabine Alternating With Intravesical BCG Randomized Against BCG Alone For Patients With Recurrent High Grade Non-Muscle Invasive Bladder Cancer | OPEN TO ACCRUAL |
|
| 104248 | A Phase 2 Multicenter, Open-Label Study Evaluating the Efficacy and Safety of TYRA-300 in Participants with FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer (SURF302) | OPEN TO ACCRUAL |
|
| 104247 | E-Care Breast Cancer Risk Assessment Study | OPEN TO ACCRUAL |
|
| 104245 | A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer | OPEN TO ACCRUAL |
|
| 104244 | Evaluating the Impact of TrialTalk™ to Foster Equitable Cancer Care Delivery and Clinical Trial Participation | OPEN TO ACCRUAL |
|
| 104243 | A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | OPEN TO ACCRUAL |
|
| 104241 | A Phase 1a/1b Study of NRM-823 as Monotherapy and in Combination with Immune Checkpoint Inhibition in Participants with Locally Advanced or Metastatic Refractory Solid Tumors | OPEN TO ACCRUAL |
|
| 104238 | A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100) | OPEN TO ACCRUAL |
|
| 104234 | AYA Access: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients | OPEN TO ACCRUAL |
|
| 104233 | A Phase 1, First-in-Human, Open-label, Multicenter Study of JZP898 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors | OPEN TO ACCRUAL |
|
| 104231 | Health Education Approach to Lung Screening (HEALS) - Lung Cancer Screening and Biospecimen Collection Through a Patient Navigation Approach | OPEN TO ACCRUAL |
|
| 104225 | An Open-Label, Sponsor-Blinded, Randomized, Controlled, Multicenter, Phase III Study of Trastuzumab Deruxtecan (T-DXd) Plus Rilvegostomig or Pembrolizumab vs Chemotherapy Plus Pembrolizumab as First-Line Therapy of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR), Primary Advanced or Recurrent Endometrial Cancer. | OPEN TO ACCRUAL |
|
| 104222 | Short Term Intensified Pembrolizumab (Keytruda) And Tivozanib For High-Risk Renal Cell Carcinoma (STRIKE) | OPEN TO ACCRUAL |
|
| 104221 | A Multi-Center Screening Study to Characterize the Prevalence of the KIT D816V Mutation in Patients with Suspected Clonal Mast Cell Disease | OPEN TO ACCRUAL |
|
| 104219 | MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials | OPEN TO ACCRUAL |
|
| 104216 | Genetic Registry for Upper Tract Urothelial Carcinoma | OPEN TO ACCRUAL |
|
| 104215 | The Effectiveness of Screening Women with Lower Genital Tract Neoplasia or Cancers for Anal Cancer Precursors. | OPEN TO ACCRUAL |
|
| 104214 | Hypofractionated Radiotherapy with a Focal Microboost for High-Risk and Locally Advanced Prostate Cancer | OPEN TO ACCRUAL |
|
| 104209 | Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics | OPEN TO ACCRUAL |
|
| 104207 | Varenicline for e-cigarette cessation | OPEN TO ACCRUAL |
|
| 104206 | cfDNA Assay Multicenter Prospective Observational Validation for Early Cancer Detection, Minimal Residual Disease, and Relapse (CAMPERR) | OPEN TO ACCRUAL |
|
| 104205 | A Phase 1/2, Open-label, Dose-escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654) in Patients with Intermediate or High-risk Primary or Secondary Myelofibrosis | OPEN TO ACCRUAL |
|
| 104204 | Specimen Collection from Participants Due for Colorectal Cancer Screening, Surveillance, or Treatment: "IMPACT" | OPEN TO ACCRUAL |
|
| 104203 | Synoptic procedural reporting to improve quality indicators in systematic Staging Endobronchial Ultrasound (EBUS) in Non-small cell lung cancer (NSCLC) | OPEN TO ACCRUAL |
|
| 104202 | Engaging Pharmacists to Advance Tobacco Treatment Service Delivery for People Living with HIV | OPEN TO ACCRUAL |
|
| 104201 | WATER IV Prostate Cancer: Aquablation versus Radical Prostatectomy for the Treatment of Localized Prostate Cancer | OPEN TO ACCRUAL |
|
| 104200 | A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors | OPEN TO ACCRUAL |
|
| 104197 | NRG-GU013: The Phase III High Five Trial' Five Fraction Radiation for High-Risk Prostate Cancer | OPEN TO ACCRUAL |
|
| 104196 | Randomized, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab and Docetaxel Versus Docetaxel Monotherapy in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy | OPEN TO ACCRUAL |
|
| 104194 | Expanded Access Program (EAP) for Obecabtagene Autoleucel (obe-cel) Out-of-specification (OOS) in Adult Patients with Acute Lymphoblastic Leukemia | OPEN TO ACCRUAL |
|
| 104192 | LOTAM: A RANDOMIZED, PHASE III CLINICAL TRIAL OF LOW-DOSE TAMOXIFEN FOR SELECTED PATIENTS WITH MOLECULAR LOW-RISK EARLY-STAGE BREAST CANCER | OPEN TO ACCRUAL |
|
| 104186 | A Randomized Phase III Clinical Trial For The Addition Of Docetaxel To Androgen Receptor Pathway Inhibitors In Patients With Metastatic Castration Sensitive Prostate Cancer And Suboptimal PSA Response (TRIPLE-SWITCH) | OPEN TO ACCRUAL |
|
| 104185 | A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab Vedotin Regimens in Subjects with Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer | OPEN TO ACCRUAL |
|
| 104178 | Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation (MajesTEC-4) | OPEN TO ACCRUAL |
|
| 104177 | A Phase III, Open-Label, Multi-Center, Randomized Study Comparing AAA817 Plus ARPI Versus Standard of Care in Adult Participants with PSMA-Positive Metastatic Castration Resistant Prostate Cancer | OPEN TO ACCRUAL |
|
| 104176 | A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma | OPEN TO ACCRUAL |
|
| 104174 | A Phase 3, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of UGN-104, a Novel Formulation of UGN-101, for the Treatment of Patients With Low-grade Upper Tract Urothelial Cancer (LG-UTUC) | OPEN TO ACCRUAL |
|
| 104171 | Perioperative Versus Adjuvant Systemic Therapy in Patients with Resectable Non-Small Cell Lung Cancer- Prospect Lung | OPEN TO ACCRUAL |
|
| 104169 | A Multicenter Randomized Trial of EBUS-TBNA versus Transbronchial Mediastinal Cryobiopsy for Adequacy of Next Generation Sequencing: FROSTBITE-3 | OPEN TO ACCRUAL |
|
| 104165 | Randomized Phase 2 Trial of Sacituzumab Govitecan With or Without Pembrolizumab in First-line Metastatic PD-L1-negative TNBC | OPEN TO ACCRUAL |
|
| 104163 | Investigating Lipid Biomarkers in Head and Neck Cancer | OPEN TO ACCRUAL |
|
| 104161 | A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer | OPEN TO ACCRUAL |
|
| 104156 | A Randomized, Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) Plus R-CHP Versus Polatuzumab Vedotin Plus R-CHP in Treatment-nave Participants With GCB Subtype of Diffuse Large B-cell Lymphoma (DLBCL) | OPEN TO ACCRUAL |
|
| 104154 | A Randomized Phase III Study of BRAF-Targeted Therapy vs Cabozantinib in RAI-Refractory Differentiated Thyroid Cancer with BRAF V600Em | OPEN TO ACCRUAL |
|
| 104150 | A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus Investigator's Choice of Therapy Comprising Either Docetaxel or Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) - rechARge | OPEN TO ACCRUAL |
|
| 104146 | Randomized Phase II study of the Addition of Targeted Therapeutic Agents to Tafasitamab-based Therapy in Non-Transplant-Eligible Patients With Relapsed/Refractory Large B-cell Lymphoma | OPEN TO ACCRUAL |
|
| 104144 | A Phase 1, Open-Label, Multicenter Study of JANX007 in Subjects with Metastatic Castration-Resistant Prostate Cancer | OPEN TO ACCRUAL |
|
| 104139 | A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING EFFICACY AND SAFETY OF GIREDESTRANT COMPARED WITH FULVESTRANT, BOTH COMBINED WITH A CDK4/6 INHIBITOR, IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE ADVANCED BREAST CANCER WITH RESISTANCE TO PRIOR ADJUVANT ENDOCRINE THERAPY | OPEN TO ACCRUAL |
|
| 104138 | Priorities, Preferences, and Tradeoffs Among Older Adults with Oropharyngeal Cancer | OPEN TO ACCRUAL |
|
| 104136 | Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE) | OPEN TO ACCRUAL |
|
| 104131 | Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma: a Single Institution Phase II Trial | OPEN TO ACCRUAL |
|
| 104127 | Transdisciplinary Oral/Oropharyngeal lesions Research & Care in Head and Neck Cancer (TORCH 2.0): A Prospective Non-Randomized Cohort Study by the Head and Neck Oncology Group (HNOG) at the Medical University of South Carolina (MUSC) | OPEN TO ACCRUAL |
|
| 104125 | Exploratory Analysis of Metastatic Gynecologic Cancer Patient Experiences of Symptom Management in a Diverse Southeastern Population | OPEN TO ACCRUAL |
|
| 104122 | Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT) | OPEN TO ACCRUAL |
|
| 104121 | NRG-CC012CD: Managing Symptoms and Psychological Distress During Oral Anti-Cancer Treatment (Symon) | OPEN TO ACCRUAL |
|
| 104120 | Randomized Phase III Study of Mosunetuzumab vs. Rituximab for low Tumor Burden Follicular Lymphoma | OPEN TO ACCRUAL |
|
| 104114 | A Phase I, First-in-human, Open-label, Dose Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BNT317 in Patients With Advanced Solid Tumors | OPEN TO ACCRUAL |
|
| 104113 | A Non-randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers SOROCk | OPEN TO ACCRUAL |
|
| 104112 | A Phase 3, Multi-center, Double-blind, 2-part Study in Participants with KRAS G12C-Mutant, Non-Small Cell Lung Cancer Comparing the Efficacy and Safety of Olomorasib in Combination with Standard of Care to Placebo in Combination with Standard of Care as Adjuvant Treatment after Platinum-based Chemotherapy | OPEN TO ACCRUAL |
|
| 104111 | A Novel Harm Reduction Approach for Oncology Outpatients who Smoke and Refuse Traditional Tobacco Treatment | OPEN TO ACCRUAL |
|
| 104110 | A Randomized Phase III Trial of Doxorubicin +Pembrolizumab Versus Doxorubicin Alone for the Treatment of Undifferentiated Pleomorphic Sarcoma (UPS) and Related Poorly Differentiated Sarcomas | OPEN TO ACCRUAL |
|
| 104108 | Phase 3 Study of Bomedemstat vs Best Available Therapy for 2L Essential Thrombocythemia | OPEN TO ACCRUAL |
|
| 104105 | A Randomized Phase II Study of Venetoclax and HMA-based Therapies for theTreatment of Older and Unfit Adults With Newly Diagnosed for FLT-3 Mutated Acute Myeloid Leukemia (AML): a MyeloMATCH Treatment Trial | OPEN TO ACCRUAL |
|
| 104095 | IMproving Proactive Approaches for Cancer survivors' mental health Treatment | OPEN TO ACCRUAL |
|
| 104093 | Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of RecurrenceA Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT) | OPEN TO ACCRUAL |
|
| 104085 | A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Efficacy of Visugromab in Combination with Pembrolizumab, Pemetrexed, and Cis- /Carboplatin in Participants with Newly Diagnosed Metastatic Non-Squamous Non-Small Cell Lung Cancer | OPEN TO ACCRUAL |
|
| 104082 | A Phase 1, open-label, dose-escalation and dose-expansion study evaluating AO-252, a protein-protein interaction inhibitor of TACC3, in patients with advanced solid tumors with or without brain metastases | OPEN TO ACCRUAL |
|
| 104079 | A Prospective Trial of Varenicline and Incentives for E-Cigarette Cessation in Adults Who Co-Use Cannabis | OPEN TO ACCRUAL |
|
| 104077 | A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma | OPEN TO ACCRUAL |
|
| 104069 | Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA) | OPEN TO ACCRUAL |
|
| 104067 | A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable older adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study | OPEN TO ACCRUAL |
|
| 104066 | Randomized controlled trial of varenicline to treat tobacco and cannabis co-use | OPEN TO ACCRUAL |
|
| 104065 | Evaluating a tobacco harm reduction strategy among clients enrolled in substance use disorder treatment | OPEN TO ACCRUAL |
|
| 104063 | A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Nave Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib | OPEN TO ACCRUAL |
|
| 104061 | Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma | OPEN TO ACCRUAL |
|
| 104060 | NeoCARD: A Response-Adapted Phase II Study of Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple-Negative Breast Cancer Patients with Cardiomyopathy or Elevated Risk of Cardiotoxicity | OPEN TO ACCRUAL |
|
| 104055 | A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) | OPEN TO ACCRUAL |
|
| 104051 | A Randomized Phase II Study of Nivolumab versus Nivolumab and BMS-986016 (Relatimab) as Maintenance Treatment after First-line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus- Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN) | OPEN TO ACCRUAL |
|
| 104049 | Dual use of combustible and electronic cigarettes: A fine-grained naturalistic cohort study to investigate dynamic use patterns and trajectories that lead to smoking cessation | OPEN TO ACCRUAL |
|
| 104042 | MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer | OPEN TO ACCRUAL |
|
| 104020 | A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects with Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | OPEN TO ACCRUAL |
|
| 104019 | Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer | OPEN TO ACCRUAL |
|
| 104014 | A Randomized, Multicenter, Phase III Trial of Tacrolimus/Methotrexate/Ruxolitinib versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation | OPEN TO ACCRUAL |
|
| 104013 | A Phase 2 Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | OPEN TO ACCRUAL |
|
| 104000 | A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON) | OPEN TO ACCRUAL |
|
| 103995 | The PROACT LUNG Study: A Prospective Observational Clinical Validation Study of the Freenome Multiomics Blood Test for Lung Cancer Screening | OPEN TO ACCRUAL |
|
| 103989 | A First-in-Human, Phase 1/2, Open-Label, Multi-Center, Dose Escalation, Dose-Optimization, and Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of PARP1 Selective Inhibitor, IMP1734, in Patients with Advanced Solid Tumors | OPEN TO ACCRUAL |
|
| 103985 | A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score 25 (OFSET) | OPEN TO ACCRUAL |
|
| 103984 | OPTIMICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients who Achieve PCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy | OPEN TO ACCRUAL |
|
| 103982 | Phase 3 Randomized Open-label Study of Adjuvant Pembrolizumab W/WO MK2870 in Resectable Stages II-IIIB(N2) NSCLC for Patients not AchievingpCR After Receiving Neoadjuvant Pembrolizumab with Platinum-Based Doublet Chemotherapy Followed by Surgery | OPEN TO ACCRUAL |
|
| 103979 | Phase I trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma | OPEN TO ACCRUAL |
|
| 103974 | A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1311 in Subjects with Advanced/Metastatic Solid Tumors | OPEN TO ACCRUAL |
|
| 103973 | PHASE II STUDY EVALUATING NALIRIFOX VS. MODIFIED GEMCITABINE, NAB-PACLITAXEL, AND CISPLATIN IN PATIENTS WITH LOCALLY ADVANCED AND METASTATIC PANCREATIC ADENOCARCINOMA | OPEN TO ACCRUAL |
|
| 103972 | Scale and Evaluate Smoking Cessation and COPD Screening E Visits to Rural Health Clinics | OPEN TO ACCRUAL |
|
| 103969 | Preclinical Evaluation of CAR T Cell Function: In Vitro, Ex Vivo, Tumor Derived Organoids and In Vivo Brain Tumor Models | OPEN TO ACCRUAL |
|
| 103968 | A Global Pivotal Study in Patients with KRAS G12C-Mutant, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Comparing First-Line Treatment of Pembrolizumab and LY3537982 vs Pembrolizumab and Placebo in those with PD-L1 50% or Pembrolizumab, Pemetrexed, Platinum Chemotherapy and LY3537982 vs Pembrolizumab, Pemetrexed, Platinum Chemotherapy and Placebo regardless of PD-L1 Expression | OPEN TO ACCRUAL |
|
| 103965 | Refining Tamoxifen Dose for Premenopausal Breast Cancer Prevention (RENAISSANCE): A Phase II Single Arm Trial | OPEN TO ACCRUAL |
|
| 103964 | The impact of cannabis and tobacco/nicotine product co-use in young adults: Prospective cessation evaluation and substitution | OPEN TO ACCRUAL |
|
| 103958 | Phase 3 Study of Epcoritamab, Rituximab, and Lenalidomide for First-Line Treatment of Follicular Lymphoma | OPEN TO ACCRUAL |
|
| 103955 | A Phase 1 Open Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications | OPEN TO ACCRUAL |
|
| 103951 | A Multicenter, Randomized, Double-blind, Phase 2/3 Study of Ficerafusp Alfa (BCA101) or Placebo in Combination with Pembrolizumab for First-Line Treatment of PD-L1-positive, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | OPEN TO ACCRUAL |
|
| 103950 | An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer | OPEN TO ACCRUAL |
|
| 103947 | TEMPUS GEMINI NSCLC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients with Non-Small Cell Lung Cancer (NSCLC) | OPEN TO ACCRUAL |
|
| 103945 | A Phase 2, Randomized Study to Evaluate the Safety, Efficacy and Optimal dose of ABBV-400 in Combination with Fluorouracil (5-FU), Folinic Acid and Bevacizumab in Previously Treated Subjects with Unresectable Metastatic Colorectal Cancer (mCRC) | OPEN TO ACCRUAL |
|
| 103940 | Rapid Onsite Cytopathologic Evaluation for Improved Molecular Marker Testing via Endobronchial Ultrasound Bronchoscopy - A Randomized Controlled Trial | OPEN TO ACCRUAL |
|
| 103936 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Ficlatuzumab in Combination with Cetuximab in Participants with Recurrent or Metastatic (R/M) HPV-Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN) | OPEN TO ACCRUAL |
|
| 103921 | A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immunooncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma. | OPEN TO ACCRUAL |
|
| 103919 | Autophagy Maintenance (AUTOMAIN) Therapy in High-Grade Serous Ovarian Cancer: A Phase II Trial | OPEN TO ACCRUAL |
|
| 103915 | A Randomized Phase II Study of INC280 (Capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study) | OPEN TO ACCRUAL |
|
| 103914 | A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal-Tec), and Investigator's Choice of Either Elotuzumab, Pomalidomide, and Dexamethasone (EPd) or Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Participants with Relapsed or Refractory Myeloma who Have Received 1 to 4 Prior Lines of Therapy Including an Anti-CD38 Antibody and Lenalidomide | OPEN TO ACCRUAL |
|
| 103913 | A Phase III Randomized Trial of Heated Intraperitoneal Chemotherapy (HIPEC) with Cisplatin versus no HIPEC at the Time of Optimal Interval Cytoreductive Surgery followed by Niraparib Maintenance in Patients with Newly Diagnosed Stage III and IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | OPEN TO ACCRUAL |
|
| 103909 | A Phase II Study of Fingolimod in Patients with Non-Small Cell and Small Cell Lung Cancer | OPEN TO ACCRUAL |
|
| 103904 | Southeastern Consortium for Lung Cancer Health Equity (SC3) Biospecimen Repository | OPEN TO ACCRUAL |
|
| 103902 | A clinical trial of adaptive treatment for early smoking cessation relapse | OPEN TO ACCRUAL |
|
| 103898 | A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physicians Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy | OPEN TO ACCRUAL |
|
| 103891 | A Stepped Wedge Cluster Randomized Trial Comparing a Navigation-Based Multilevel Intervention With Treatment as Usual to Improve Initiation of Timely Postoperative Radiation Therapy in Adults with Locally Advanced Head and Neck Squamous Cell Carcinoma (The ENDURE Trial) | OPEN TO ACCRUAL |
|
| 103878 | A Prospective, Phase 3 Study of Patients with Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | OPEN TO ACCRUAL |
|
| 103873 | A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T Cell Treatment for Relapsed/Refractory Large B Cell Lymphoma or Grade IIIB Follicular Lymphoma | OPEN TO ACCRUAL |
|
| 103848 | Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC) | OPEN TO ACCRUAL |
|
| 103837 | Randomized Phase III Trial of M-Folfirinox +/- Nivolumab vs. Folfox +/- Nivolumab for First Line Treatment of Metastatic HER-2 Negative Gastroesophageal Addenocarcinoma | OPEN TO ACCRUAL |
|
| 103825 | Non-cigarette tobacco products as harm reduction tools in smokers who failed to quit with traditional methods | OPEN TO ACCRUAL |
|
| 103807 | Addressing Rural Cancer Disparities via Proactive Smoking Cessation Treatment within Primary Care: A Hybrid Type 1 Effectiveness-Implementation Trial of a Scalable Smoking Cessation Electronic Visit | OPEN TO ACCRUAL |
|
| 103799 | A CONTROLLED, RANDOMIZED PHASE II TRIAL OF DOCETAXEL PLUS TRASTUZUMAB VERSUS ADO-TRASTUZUMAB EMTANSINE FOR RECURRENT, METASTATIC, OR TREATMENT-NAVE, UNRESECTABLE HER2-POSITIVE SALIVARY GLAND CANCER | OPEN TO ACCRUAL |
|
| 103784 | A Phase 2 Open-Label, Multicenter Clinical Study of the Safety, Efficacy, Pharmacokinetic, and Pharmacodynamic Profiles of CGT9486 as a Single Agent in Patients With Advanced Systemic Mastocytosis | OPEN TO ACCRUAL |
|
| 103779 | A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Patients with Acute Leukemia and Other Selected Hematologic Malignancies, with and without Mixed Lineage Leukemia (MLL) rearrangement or Nucleophosmin 1 (NPM1) Mutation | OPEN TO ACCRUAL |
|
| 103757 | Impact of cigarette and e-cigarette menthol regulation on current smokers of menthol cigarettes. | OPEN TO ACCRUAL |
|
| 103749 | A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA OR CARCINOSARCOMA | OPEN TO ACCRUAL |
|
| 103745 | Neoadjuvant Screening Trial: LCMC4 Evaluation of Actionable Drivers in Early Stage Lung Cancer | OPEN TO ACCRUAL |
|
| 103733 | A Multi-Site Randomized Clinical Trial Comparing a Brief Tele-Cognitive Behavioral Therapy Intervention (BRIGHT) with Attention Control for the Management of Body Image-Related Distress Among Head and Neck Cancer Survivors | OPEN TO ACCRUAL |
|
| 103713 | A Phase II Study of Naxitamab Added to Induction Therapy for Subjects with Newly Diagnosed High-Risk Neuroblastoma | OPEN TO ACCRUAL |
|
| 103706 | UF-HN-004 Risk Adapted De-Intensification of Radio-Chemotherapy for Favorable Prognosis Oropharyngeal Squamous Cell Carcinoma based on HPV subtype and plasma circulating free HPV DNA Level and Clearance Rate. | OPEN TO ACCRUAL |
|
| 103683 | A Randomized Phase 3 Study Assessing the Efficacy and Safety of Olvi-Vec followed by Platinum-doublet Chemotherapy and Bevacizumab Compared with Platinum-doublet Chemotherapy and Bevacizumab in Women with Platinum-Resistant/Refractory Ovarian Cancer (OnPrime/GOG-3076 Study) | OPEN TO ACCRUAL |
|
| 103664 | Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients with Post-ProstaTEctomy Biochemical Recurrence (INDICATE) | OPEN TO ACCRUAL |
|
| 103649 | Collection of Blood to Evaluate Epigenomics and Protein Biomarkers for the Detection of Hepatocellular Carcinoma | OPEN TO ACCRUAL |
|
| 103644 | Pilot Study to Evaluate Circulating Tumor DNA in Classical Hodgkin Lymphoma and Primary Mediastinal Large B cell Lymphoma | OPEN TO ACCRUAL |
|
| 103624 | A Phase II Study of Ribociclib And Endocrine Treatment of Physician s Choice for Locoregional Recurrent Resected Hormone Receptor Positive HER2 Negative Breast Cancer | OPEN TO ACCRUAL |
|
| 103598 | Pediatric Acute Leukemia (PedAL) Screening Trial Developing New Therapies for Relapsed Leukemias | OPEN TO ACCRUAL |
|
| 103588 | Randomized Phase II Trial of Postoperative Adjuvant Capecitabine and Temozolomide Versus Observation in High-Risk Pancreatic Neuroendocrine Tumors | OPEN TO ACCRUAL |
|
| 103573 | Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | OPEN TO ACCRUAL |
|
| 103538 | A Randomized Controlled Trial to Evaluate the Survivorship Needs Assessment Planning Tool for Head and Neck Cancer Survivor-Caregiver Dyads | OPEN TO ACCRUAL |
|
| 103517 | Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer | OPEN TO ACCRUAL |
|
| 103509 | Hybrid Type 1 Effectiveness-Implementation Trial of a Proactive Smoking Cessation Electronic Visit for Scalable Delivery via Primary Care | OPEN TO ACCRUAL |
|
| 103507 | A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor | OPEN TO ACCRUAL |
|
| 103506 | A Phase 3 Randomized Non Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1) | OPEN TO ACCRUAL |
|
| 103472 | T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer | OPEN TO ACCRUAL |
|
| 103454 | A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy | OPEN TO ACCRUAL |
|
| 103414 | Unbiased Discovery and Validation of Serum Auto Antibodies in Patients with Rheumatic Immune Related Adverse Events Due to Immune Checkpoint Inhibitors | OPEN TO ACCRUAL |
|
| 103411 | Randomized, Phase III Study of Early Intervention With Venetoclax and Obinutuzumab Versus Delayed Therapy With Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study | OPEN TO ACCRUAL |
|
| 103406 | A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas | OPEN TO ACCRUAL |
|
| 103388 | Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation | OPEN TO ACCRUAL |
|
| 103387 | Prospective ctDNA Monitoring in Exceptional Responders to Immunotherapy: A Pilot Study | OPEN TO ACCRUAL |
|
| 103383 | Optimizing Tobacco Treatment Delivery for People Living with HIV | OPEN TO ACCRUAL |
|
| 103380 | Internet-delivered Management of Pain Among Cancer Treatment Survivors (IMPACTS) | OPEN TO ACCRUAL |
|
| 103377 | Specimen Banking With Clinical and Genomic Data Registry With the Establishment of Tumor Models for Pediatric Cancers | OPEN TO ACCRUAL |
|
| 103371 | Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma | OPEN TO ACCRUAL |
|
| 103362 | EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE | OPEN TO ACCRUAL |
|
| 103361 | Non-invasive imaging technologies in Dermatology | OPEN TO ACCRUAL |
|
| 103351 | A Phase 1B Dose Escalation Study Of Metabolically Fit CD19 Chimeric Antigen Receptor (CAR) T Cells With CD34 Selection Markers In Adult Patients With Relapsed Or Refractory CD19 B- Cell Non-Hodgkin Lymphoma And Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | OPEN TO ACCRUAL |
|
| 103341 | First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGF- Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors | OPEN TO ACCRUAL |
|
| 103335 | Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel That is Nonconforming for Commercial Release | OPEN TO ACCRUAL |
|
| 103329 | Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT) | OPEN TO ACCRUAL |
|
| 103328 | A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy | OPEN TO ACCRUAL |
|
| 103319 | Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial | OPEN TO ACCRUAL |
|
| 103312 | A Phase 3 Randomized Trial for Patients With De Novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 With GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients With FLT3 Mutations | OPEN TO ACCRUAL |
|
| 103247 | LUNGMAP: A Master Protocol To Evaluate Biomarker-Driven Therapies And Immunotherapies In Previously-Treated Non-Small Cell Lung Cancer (Lung-Map Screening Study) | OPEN TO ACCRUAL |
|
| 103220 | InPACT International Penile Advanced Cancer Trial (International Rare Cancers Initiative study) | OPEN TO ACCRUAL |
|
| 103168 | A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC) | OPEN TO ACCRUAL |
|
| 103147 | GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent Glioblastoma (GBM) | OPEN TO ACCRUAL |
|
| 103096 | A Randomized Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-Risk Germ Cell Tumors | OPEN TO ACCRUAL |
|
| 103043 | The Impact of a Gravity versus Vacuum Based Indwelling Tunneled Pleural Drainage System on Pain: A Multicenter, Randomized Trial | OPEN TO ACCRUAL |
|
| 103041 | Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) or large b-cell lymphoma patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release | OPEN TO ACCRUAL |
|
| 103013 | A Phase II Study of Metronomic and Targeted Anti-Angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma | OPEN TO ACCRUAL |
|
| 103008 | PHASE III RANDOMIZED TRIAL OF STANDARD SYSTEMIC THERAPY (SST) VERSUS STANDARD SYSTEMIC THERAPY PLUS DEFINITIVE TREATMENT (SURGERY OR RADIATION) OF THE PRIMARY TUMOR IN METASTATIC PROSTATE CANCER | OPEN TO ACCRUAL |
|
| 102968 | Health Effects After Anthracycline and Radiation Therapy (HEART): Dexrazoxane and Prevention of Anthracycline-Related Cardiomyopathy | OPEN TO ACCRUAL |
|
| 102946 | A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors | OPEN TO ACCRUAL |
|
| 102945 | A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379) | OPEN TO ACCRUAL |
|
| 102483 | Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP) | OPEN TO ACCRUAL |
|
| 102449 | The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study | OPEN TO ACCRUAL |
|
| 102438 | PEDS-PLAN - Pediatric Precision Laboratory Advanced Neuroblastoma Therapy- A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma | OPEN TO ACCRUAL |
|
| 101774 | A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units (CBUs) Manufactured by the National Cord Blood Program (NCBP) and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients | OPEN TO ACCRUAL |
|
| 101593 | A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications | OPEN TO ACCRUAL |
|
| 101547 | Hollings Cancer Center Tissue Biorepository | OPEN TO ACCRUAL |
|
| 101259 | Umbrella Long-Term Follow-Up Protocol | OPEN TO ACCRUAL |
|
| 100720 | Protocol for a Research Sample Repository for Allogeneic Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries | OPEN TO ACCRUAL |
|
| 100719 | Protocol for a Research Database for Hematopoietic Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries | OPEN TO ACCRUAL |
|
| Lung Cancer Screening, Lung Nodule, and Lung Cancer Biorepository | OPEN TO ACCRUAL |
|